biology3 papersavg year 2026weak evidence

The molecular events that occur during early esophageal

Research gap analysis derived from 3 biology papers in our local library.

The gap

The molecular events that occur during early esophageal carcinogenesis are not well understood. Systematic molecular characterization of early human ESCC precursor lesions remains challenging. There is a need to better understand the molecu

Evidence profile

Sourced from the stated research gap and abstract of the source papers, classified as general, spanning 2 journals.

Research trend

Established — well-defined area with open sub-problems.

Supporting evidence — 3 representative gaps

  • Temporal Transcriptomic Profiling of NMBA-Induced Rat Esophageal Squamous Carcinogenesis Identifies Early Inflammatory Activation and Late NRF2-Associated Oxidative-Stress Remodeling (2026) · International Journal of Molecular Sciences · doi

    The molecular events that occur during early esophageal carcinogenesis are not well understood. Systematic molecular characterization of early human ESCC precursor lesions remains challenging. There is a need to better understand the molecular events that occur during early esophageal carcinogenesis to inform prevention, early detection, and mechanism-based intervention.

    generalstated research gap
    Keywords: molecular events occur during early esophageal carcinogenesis well
  • PD04.03. SMYD2 as a Novel Molecular Regulator of Immune Evasion and Immunosuppression in Esophagogastric Junction Cancer (2026) · Diseases of the Esophagus · doi

    Abstract Topic Esophageal Cancer: Molecular Biology/Pathology Background Immune checkpoint inhibitors targeting PD-1/PD-L1 have caused a paradigm shift in esophageal and gastric cancer treatment; however, oncogenic mechanisms regulating immune evasion and Treg-mediated immunosuppression remain unclear.

    generalabstractevidence 5/5
    Keywords: esophageal cancer immune abstract topic molecular biology pathology background checkpoint inhibitors targeting caused paradigm shift
  • P1.074. SNORD33-Driven 18S rRNA 2′-O-Methylation Licenses TNFSF9–4-1BB Signaling and Sensitizes ESCC to PD-1 Blockade (2026) · Diseases of the Esophagus · doi

    Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Neoadjuvant PD-1/PD-L1 based immunotherapy improve outcomes for resectable esophageal squamous cell carcinoma (ESCC), but patient outcome are heterogeneous and robust pretreatment blood biomarkers are lacking.

    generalabstractevidence 5/5
    Keywords: esophageal adjuvant abstract topic cancer therapies background neoadjuvant based immunotherapy improve outcomes resectable squamous cell

Questions about this gap

The molecular events that occur during early esophageal carcinogenesis are not well understood. Systematic molecular characterization of early human ESCC precursor lesions remains… This is supported by 3 representative gap statements extracted from 3 papers, rated weak evidence.

Explore this gap further

Run this gap as a query across open scholarly engines for the latest related literature.

Working on this gap? Review it with us.

Science AI Journal reviews manuscripts in one pass with 8 specialised AI agents calibrated on 69,000+ real peer reviews.

Related gaps in Biology

Command palette

Jump anywhere, run any action.